Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226574 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain
A Phase 1 study of Intractable Cancer Pain, sponsored by Sorrento Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
- 4
- Study locations
NCT03226574: Completed Phase 1 study of Intractable Cancer Pain, sponsored by Sorrento Therapeutics.
NCT03226574 is a Phase 1 study of Intractable Cancer Pain that has completed, run by Sorrento Therapeutics. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03226574, a Phase 1 study of Intractable Cancer Pain, has completed, sponsored by Sorrento Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult subjects with intractable pain associated with cancer in any area below the mid-thoracic level who meet all other eligibility criteria.
Primary Outcome
Grade 3 or 4 Toxicity associated with RTX administration
Conditions Studied
Interventions
- DRUG Resiniferatoxin
Study Locations (4)
Florida
- University of Miami/Sylvester Comprehensive Cancer Center - Miami
Massachusetts
- Brigham & Women's Hospital - Boston
North Carolina
- Duke University Medical Center - Durham
Texas
- Hermann Drive Surgical Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2020-06-18 |
| Phase | Phase 1 |
What the finished NCT03226574 record still lists
NCT03226574 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Intractable Cancer Pain appearing as the primary indexed condition, and to 1 intervention - of which Resiniferatoxin is the first listed.
NCT03226574 reports a single indexed study location in Florida, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03226574 about?
NCT03226574 is a clinical study titled "Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain". The study is a multicenter, open-label Phase 1b single dose escalation safety study for adult subjects with intractable pain associated with cancer in any area below the mid-thoracic level who meet all other eligibility criteria.
What is the current status of trial NCT03226574?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-09-01. Estimated completion is 2020-06-18.
What conditions does trial NCT03226574 study?
This clinical trial studies the following conditions: Intractable Cancer Pain.
What interventions are being tested in trial NCT03226574?
The interventions under investigation include: Resiniferatoxin (DRUG).
Who is sponsoring clinical trial NCT03226574?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03226574 being conducted?
This trial has 4 study locations across Florida, Massachusetts, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03226574's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI